Medicase - Bizoran 5/40 - 15 Tablets - 5mg+40mg - Amlodipine + Olmesartan Medoxomil

Bizoran 5/405mg+40mg

Type:15 Tablets

Generic Name:Amlodipine + Olmesartan Medoxomil

Manufacturer:Beximco Pharmaceuticals Ltd.

Price:৳300.00

Indication

Hypertension 5 mg/20 mg PO qDay intially; may increase dose after 1-2 weeks; not to exceed 10 mg/40 mg May be adminsitered concomitantly with other antihypertensive agents Elderly: May consider lower starting dose. Hepatic Impairment: Caution in patients with mild to moderate hepatic impairment.

Administration

Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers. Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.

Adult Dose

Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal & hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation. Lactation: It is not known whether the amlodipine or olmesartan are excreted in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Child Dose

Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters).

Renal Dose

Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina. Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.

Mode of Action

May be taken with or without food.

Precaution

Hypertension

Side Effect

Avoid use in severe renal impairment (CrCl< 20 mL/min).

Pregnancy Category Note

>10% Peripheral edema (11%) Frequency Not Defined Palpitation,Nocturia,Urinary frequency,Orthostatic hypotension,Pruritus,Rash Potentially Fatal: Acute renal failure.